|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Jorgen Drejer Ph.D.||Founder, Chairman & Deputy CEO||N/D||N/D||1955|
|Mr. Rami Levin||Pres||7,36M||N/D||1969|
|Mr. Thomas Feldthus M.Sc., MBA||Co-Founder & CEO||N/D||N/D||1960|
|Ms. Anita Milland B.Com.||Chief Financial Officer||N/D||N/D||1968|
|Mr. Karin Sandager Nielsen Ph.D.||Chief Scientific Officer||N/D||N/D||N/D|
|Mr. Palle Christophersen M.S., Ph.D.||Exec. VP of Research||N/D||N/D||1958|
|Mr. Janus Schreiber Larsen||Chief Devel. Officer||N/D||N/D||1972|
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
L'ISS Governance QualityScore di Saniona AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.